Oncobiologics, Inc. and inVentiv Health last week announced a broad strategic partnership around clinical development for all assets in Oncobiologic’s pipeline.
The scope of the partnership is global and will initially focus on biosimilar assets, and could be expanded to include innovative molecules. Through the partnership, inVentiv Health will provide leadership and execution for clinical studies, as well as the corresponding bioanalytical support for those trials. As the assets are commercialized, the partnership will be broadened to include inVentiv’s significant commercialization capabilities in select countries. This will position Oncobiologics attractively in seeking future commercial partners.
The current biosimilar assets include generic (Editor’s note: it should be “biosimilar”, not generic for sure!) versions of Humira, Rituxan, Avastin, Herceptin and Erbitux. These biologics are the most popular therapies in the world for their respective cancer and immune-disease indications, representing annual global revenue of more than $40 billion.
“After an exhaustive global review of potential partners, we selected the broad-scale inVentiv platform as an important differentiator for our program as this partnership spans both clinical and bioanalytical development as well as commercialization of our biosimilar assets. inVentiv is able to take the scope of these agreements to a much broader level by working across the full development life cycle of each biosimilar and innovator product while preparing for a successful market launch. With their willingness to share in the risk/reward of our development programs, our firms are a perfect fit, both technically and culturally,” said Oncobiologics Founder & CEO, Pankaj Mohan, Ph.D.
Ray Hill, President, inVentiv Health Clinical added, “We are thrilled to partner with Oncobiologics and to be a part of their highly capable biosimilars consortium. With their recent global partnering successes, we look forward to helping Oncobiologics bring their biosimilar assets through clinical trials and into the marketplace. By joining their fully-integrated CMC capabilities with inVentiv’s broad clinical and commercial expertise, we are creating a venture that is truly greater than the sum of its parts.”
Source: Oncobiologics press release